The latest price target for Nuvectis Pharma (NASDAQ:NVCT) was reported by HC Wainwright & Co. on August 6, 2024. The analyst firm set a price target for $21.00 expecting NVCT to rise to within 12 months (a possible 356.52% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Nuvectis Pharma (NASDAQ:NVCT) was provided by HC Wainwright & Co., and Nuvectis Pharma reiterated their buy rating.

There is no last upgrade for Nuvectis Pharma

There is no last downgrade for Nuvectis Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on August 6, 2024 so you should expect the next rating to be made available sometime around August 6, 2025.

While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a reiterated with a price target of $21.00 to $21.00. The current price Nuvectis Pharma (NVCT) is trading at is $4.60, which is out of the analyst’s predicted range.